Increased Serum Free Light Chains Precede the Presentation of Immunoglobulin Light Chain Amyloidosis

被引:62
|
作者
Weiss, Brendan M. [1 ]
Hebreo, Joseph [2 ]
Cordaro, Daniel V. [3 ]
Roschewski, Mark J. [3 ]
Baker, Thomas P. [3 ]
Abbott, Kevin C. [3 ]
Olson, Stephen W. [3 ]
机构
[1] Univ Penn, Philadelphia, PA 19104 USA
[2] Naval Med Ctr San Diego, San Diego, CA USA
[3] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA
关键词
UNDETERMINED SIGNIFICANCE MGUS; PRIMARY SYSTEMIC AMYLOIDOSIS; MONOCLONAL GAMMOPATHY; MULTIPLE-MYELOMA; GERMLINE GENE; DIAGNOSIS; ABNORMALITIES; INVOLVEMENT; PROGRESSION; ANTIBODIES;
D O I
10.1200/JCO.2013.50.0892
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Patients with immunoglobulin light chain amyloidosis (AL amyloidosis) generally present with advanced organ dysfunction and have a high risk of early death. We sought to characterize monoclonal immunoglobulin (M-Ig) light chains before clinical presentation of AL amyloidosis. Patients and Methods We obtained prediagnostic sera from 20 cases with AL amyloidosis and 20 healthy controls matched for age, sex, race, and age of serum sample from the Department of Defense Serum Repository. Serum protein electrophoresis with immunofixation and serum free light chain (FLC) analysis were performed on all samples. Results An M-Ig was detected in 100% of cases and 0% of controls (P < .001). The M-Ig was present in 100%, 80%, and 42% of cases at less than 4 years, 4 to 11 years, and more than 11 years before diagnosis, respectively. The median FLC differential (FLC-diff) was higher in cases compared with controls at all time periods, less than 4 years (174.8 v 0.3 mg/ L; P < .001), 4 to 11 years (65.1 v 2.2 mg/ L; P < .001), and more than 11 years (4.5 v 0.4 mg/ L; P = .03) before diagnosis. The FLC-diff was greater than 23 mg/ L in 85% of cases and 0% of controls (P < .001). The FLC-diff level increased more than 10% per year in 84% of cases compared with 16% of controls (P < .001). Conclusion Increase of FLCs, including within the accepted normal range, precedes the development of AL amyloidosis for many years. (C) 2014 by American Society of Clinical Oncology
引用
收藏
页码:2699 / +
页数:7
相关论文
共 50 条
  • [1] Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains
    Sidana, S.
    Tandon, N.
    Dispenzieri, A.
    Gertz, M. A.
    Buadi, F. K.
    Lacy, M. Q.
    Dingli, D.
    Fonder, A. L.
    Hayman, S. R.
    Hobbs, M. A.
    Gonsalves, W. I.
    Hwa, Y. L.
    Kapoor, P.
    Kyle, R. A.
    Leung, N.
    Go, R. S.
    Lust, J. A.
    Russell, S. J.
    Zeldenrust, S. R.
    Rajkumar, S. V.
    Kumar, S. K.
    LEUKEMIA, 2018, 32 (03) : 729 - 735
  • [2] Optimization of Serum Immunoglobulin Free Light Chain Analysis for Subclassification of Cardiac Amyloidosis
    Halushka, Marc K.
    Eng, George
    Collins, A. Bernard
    Judge, Daniel P.
    Semigran, Marc J.
    Stone, James R.
    JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2015, 8 (04) : 264 - 268
  • [3] Immunoglobulin light chain amyloidosis
    Merlini, Giampaolo
    Comenzo, Raymond L.
    Seldin, David C.
    Wechalekar, Ashutosh
    Gertz, Morie A.
    EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (01) : 143 - 156
  • [4] Systemic immunoglobulin light chain amyloidosis
    Merlini, Giampaolo
    Dispenzieri, Angela
    Sanchorawala, Vaishali
    Schoenland, Stefan O.
    Palladini, Giovanni
    Hawkins, Philip N.
    Gertz, Morie A.
    NATURE REVIEWS DISEASE PRIMERS, 2018, 4
  • [5] Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features
    Kumar, Shaji
    Dispenzieri, Angela
    Katzmann, Jerry A.
    Larson, Dirk R.
    Colby, Colin L.
    Lacy, Martha Q.
    Hayman, Suzanne R.
    Buadi, Francis K.
    Leung, Nelson
    Zeldenrust, Steve R.
    Ramirez-Alvarado, Marina
    Clark, Raynell J.
    Kyle, Robert A.
    Rajkumar, S. Vincent
    Gertz, Morie A.
    BLOOD, 2010, 116 (24) : 5126 - 5129
  • [6] Analysis of Free Serum Light Chains in Patients Suffering from Multiple Myeloma Complicated by Light-Chain Amyloidosis
    Usnarska-Zubkiewicz, Lidia
    Holojda, Jadwiga
    Debski, Jakub
    Zubkiewicz-Zarebska, Anna
    Zagocka, Ewa
    Kuliczkowski, Kazimierz
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2014, 23 (04): : 531 - 538
  • [7] Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience
    Kourelis, Taxiarchis V.
    Kyle, Robert A.
    Dingli, David
    Buadi, Francis K.
    Kumar, Shaji K.
    Gertz, Morie A.
    Lacy, Martha Q.
    Kapoor, Prashant
    Go, Ronald S.
    Gonsalves, Wilson I.
    Warsame, Rahma
    Lust, John A.
    Hayman, Suzanne R.
    Rajkumar, S. Vincent
    Zeldenrust, Steven R.
    Russell, Stephen J.
    Lin, Yi
    Leung, Nelson
    Dispenzieri, Angela
    MAYO CLINIC PROCEEDINGS, 2017, 92 (06) : 908 - 917
  • [8] Mutations in Specific Structural Regions of Immunoglobulin Light Chains Are Associated with Free Light Chain Levels in Patients with AL Amyloidosis
    Poshusta, Tanya L.
    Sikkink, Laura A.
    Leung, Nelson
    Clark, Raynell J.
    Dispenzieri, Angela
    Ramirez-Alvarado, Marina
    PLOS ONE, 2009, 4 (04):
  • [9] Flow cytometry in immunoglobulin light chain amyloidosis: Short review
    Filipova, Jana
    Rihova, Lucie
    Vsianska, Pavia
    Kufova, Zuzana
    Kryukova, Elena
    Kryukov, Fedor
    Hajek, Roman
    LEUKEMIA RESEARCH, 2015, 39 (11) : 1131 - 1136
  • [10] Treatment of immunoglobulin light chain amyloidosis
    Gertz M.A.
    Zeldenrust S.R.
    Current Hematologic Malignancy Reports, 2009, 4 (2) : 91 - 98